Morgan Stanley Navidea Biopharmaceuticals, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.08 - $0.29 $332 - $1,203	4,150 Added 1560.15%	4,416 $0
Q1 2023 May 15, 2023	SELL	$0.24 - $0.34 $7 - $10	-31 Reduced 10.44%	266 $0
Q4 2022 Feb 14, 2023	BUY	$0.18 - $0.3 $5 - $9	31 Added 11.65%	297 $0
Q2 2022 Oct 27, 2022	SELL	$0.63 - $1.1 $160 - $279	-254 Reduced 48.85%	266 $0
Q2 2022 Aug 15, 2022	SELL	$0.63 - $1.1 $160 - $279	-254 Reduced 48.85%	266 $0

Q1 2022 Oct 27, 2022	BUY	$0.72 - $1.2 $182 - $304	254 Added 95.49%	520 $0
Q1 2022 May 13, 2022	BUY	$0.72 - $1.2 $146 - $243	203 Added 64.04%	520 $0
Q4 2021 Feb 14, 2022	SELL	$1.0 - $1.82 $2,499 - $4,548	-2,499 Reduced 88.74%	317 $0
Q3 2021 Nov 15, 2021	BUY	$1.53 - $1.85 $4,308 - $5,209	2,816 New	2,816 $5,000

10.4K

Ticker NAVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 32,150,900
Description
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expr...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.